The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.   YORVIPATH is Ascendis Pharma's prodrug of parathyroid hormone (PTH 1-34), administered once daily. Ascendis plans its first EU launch of YORVIPATH in January 2024 in Germany.  “Each patient living with chronic hypoparathyroidism […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!